The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3140-3150

  Avouac, Jérôme ^a,b   Palumbo Zerr, Katrin ^a   Ruzehaji, Nadira ^b   Tomcik, Michal ^a,c   Zerr, Pawel ^a   Dees, Clara ^a   Distler, Alfiya ^a   Beyer, Christian ^a   Schneider, Holm ^a   Distler, Oliver ^d   Schett, Georg ^a   Allanore, Yannick ^b   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; BLEOMYCIN; COLLAGEN; CONSTITUTIVE ANDROSTANE RECEPTOR; NUCLEAR RECEPTOR NR1I3; ORPHAN NUCLEAR RECEPTOR; SMAD PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; ALPHA 2(I) COLLAGEN; CELL RECEPTOR; COLLAGEN TYPE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXPERIMENTAL FIBROSIS; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; MUTAGENESIS; MYOFIBROBLAST; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; FIBROSIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADULT; AGED; ANIMALS; BLEOMYCIN; CELLS, CULTURED; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84925581570     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38819     Document Type: Article

References (45)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
3. Wynn TA, Ramalingam TR,. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-40.
4. Varga J, Pasche B,. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
5. Baes M, Gulick T, Choi HS, Martinoli MG, Simha D, Moore DD,. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 1994; 14: 1544-52.
6. Kobayashi K, Sueyoshi T, Inoue K, Moore R, Negishi M,. Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 2003; 64: 1069-75.
7. Tzameli I, Pissios P, Schuetz EG, Moore DD,. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 2000; 20: 2951-8.
8. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, et al., Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 2003; 278: 17277-83.
9. Qatanani M, Moore DD,. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab 2005; 6: 329-39.
10. Kawase A, Yoshida I, Tsunokuni Y, Iwaki M,. Decreased PXR and CAR inhibit transporter and CYP mRNA levels in the liver and intestine of mice with collagen-induced arthritis. Xenobiotica 2007; 37: 366-74.
11. Yamazaki Y, Kakizaki S, Horiguchi N, Sohara N, Sato K, Takagi H, et al., The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 2007; 56: 565-74.
12. Chakraborty S, Kanakasabai S, Bright JJ,. Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells. Br J Cancer 2011; 104: 448-59.
13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
14. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al., Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
15. Distler JH, Jungel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, et al., Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007; 56: 4203-15.
16. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al., Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012; 3: 735.
17. Choi HS, Chung M, Tzameli I, Simha D, Lee YK, Seol W, et al., Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J Biol Chem 1997; 272: 23565-71.
18. Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, et al., JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2012; 64: 3006-15.
19. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, et al., The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320-6.
20. Chen R, Huang C, Morinelli TA, Trojanowska M, Paul RV,. Blockade of the effects of TGF-β1 on mesangial cells by overexpression of Smad7. J Am Soc Nephrol 2002; 13: 887-93.
21. Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, et al., Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Ann Rheum Dis 2014; 73: 1215-22.
22. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al., Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52: 856-64.
23. Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al., Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006; 54: 214-25.
24. Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K, et al., Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011; 70: 1304-10.
25. Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, et al., Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012; 71: 737-45.
26. Schaffner F,. Primary biliary cirrhosis as a collagen disease. Postgrad Med 1979; 65: 97-102.
27. Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, et al., Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012; 64: 1642-52.
28. Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M, et al., Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013; 72: 1089-98.
29. Beyer C, Reich N, Schindler SC, Akhmetshina A, Dees C, Tomcik M, et al., Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012; 71: 1019-26.
30. Rawson AJ, Abelson NM, Hollander JL,. Studies on the pathogenesis of rheumatoid joint inflammation. II. Intracytoplasmic particulate complexes in rheumatoid synovial fluids. Ann Intern Med 1965; 62: 281-4.
31. Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P, et al., The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2013; 72: 1255-8.
32. Beyer C, Reichert H, Akan H, Mallano T, Schramm A, Dees C, et al., Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013; 72: 1255-8.
33. Lewis RB,. The absence of reactive arthritis after Shigella sonnei infection [letter]. Arthritis Rheum 1982; 25: 1267.
34. Khodzhigorova A, Distler A, Lang V, Dees C, Schneider H, Beyer C, et al., Inhibition of sumoylation prevents experimental fibrosis [published erratum appears in Ann Rheum Dis 2013;72:1110]. Ann Rheum Dis 2012; 71: 1904-8.
35. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al., Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007; 56: 334-44.
36. Kopp J, Preis E, Said H, Hafemann B, Wickert L, Gressner AM, et al., Abrogation of transforming growth factor-β signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. J Biol Chem 2005; 280: 21570-6.
37. Wieser R, Wrana JL, Massague J,. GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J 1995; 14: 2199-208.
38. Weingartner S, Zerr P, Tomcik M, Palumbo-Zerr K, Distler A, Dees C, et al., Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012; 71: 1895-9.
39. Beyer C, Schett G, Distler O, Distler JH,. Animal models of systemic sclerosis: prospects and limitations [review]. Arthritis Rheum 2010; 62: 2831-44.
40. Beyer C, Skapenko A, Distler A, Dees C, Reichert H, Munoz L, et al., Activation of pregnane X receptor inhibits experimental dermal fibrosis. Ann Rheum Dis 2013; 72: 621-5.
41. Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, et al., PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5: e13778.
42. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, et al., Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009; 23: 2968-77.
43. Wei J, Bhattacharyya S, Varga J,. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 2010; 22: 671-6.
44. Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, et al., Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012; 27: 301-6.
45. Baskin-Bey ES, Huang W, Ishimura N, Isomoto H, Bronk SF, Braley K, et al., Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology 2006; 44: 252-62.